[18F]FES PET can be employed as a predictive tool for treatment response in breast cancer patients with different types of therapy (i.e., endocrine therapy ± CDK4/6 inhibitor, neoadjuvant endocrine/chemotherapy). This evidence concerns the gene CDK4 and breast carcinoma.